Citations

Showing 10 of 108083 citations.

Inorganic nitrate supplementation attenuates peripheral chemoreflex sensitivity but does not improve cardiovagal baroreflex sensitivity in older adults
Bock, Joshua M. , Ueda, Kenichi , Schneider, Aaron , Hughes, William E. , Limberg, Jacqueline K. , Bryan, Nathan S. , Casey, Darren P. , Bock, Joshua , Hughes, William E.

Mayo Clinic

American Journal of Physiology-Heart and Circulatory Physiology | October 2, 2017 | Volume: 314 | Issue: 1 | Pages: H45-H51

10.1152/ajpheart.00389.2017 | PMID 28971842 Get It

Aging is associated with increased peripheral chemoreceptor activity, reduced nitric oxide (NO) bioavailability, and attenuation of cardiovagal baroreflex sensitivity (BRS), collectively increasing the risk of cardiovascular disease. Evidence suggests that NO may attenuate peripheral chemoreflex sensitivity and increase BRS. Exogenous inorganic nitrate ([Formula: see text]) increases NO bioavailability via the [Formula: see text]-[Formula: see text]-NO pathway. Our hypothesis was that inorganic [Formula: see text] supplementation would attenuate peripheral chemoreflex sensitivity and enhance spontaneous cardiovagal BRS in older adults. We used a randomized, placebo-controlled crossover design in which 13 older (67 ± 3 yr old) adults ingested beetroot powder containing (BRA) or devoid of (BRP) [Formula: see text] and [Formula: see text] daily over 4 wk. Spontaneous cardiovagal BRS was assessed over 15 min of rest and was quantified using the sequence method. Chemoreflex sensitivity was assessed via ~5 min of hypoxia (10% fraction of inspired O2) and reported as the slope of the relationship between O2 saturation (%[Formula: see text]) and minute ventilation (in l/min) or heart rate (in beats/min). Ventilatory responsiveness to hypoxia was reduced after BRA (from −0.14 ± 0.04 to −0.05 ± 0.02 l·min−1·%[Formula: see text]−1, P = 0.01) versus BRP (from −0.10 ± 0.05 to −0.11 ± 0.05 l·min−1·%[Formula: see text]−1, P = 0.80), with no differences in heart rate responsiveness (BRA: from −0.47 ± 0.06 to −0.33 ± 0.04 beats·min−1·%[Formula: see text]−1, BRP: from −0.48 ± 0.07 to −0.42 ± 0.06 beats·min−1·%[Formula: see text]−1) between conditions (interaction effect, P = 0.41). Spontaneous cardiovagal BRS was unchanged after BRA and BRP (interaction effects, P = 0.69, 0.94, and 0.39 for all, up, and down sequences, respectively), despite a reduction in resting systolic and mean arterial blood pressure in the experimental (BRA) group ( P < 0.01 for both). These findings illustrate that inorganic [Formula: see text] supplementation attenuates peripheral chemoreflex sensitivity without concomitant change in spontaneous cardiovagal BRS in older adults. NEW & NOTEWORTHY Exogenous inorganic nitrate supplementation attenuates ventilatory, but not heart rate, responsiveness to abbreviated hypoxic exposure in older adults. Additionally, inorganic nitrate reduces systolic and mean arterial blood pressure without affecting spontaneous cardiovagal baroreflex sensitivity. These findings suggest that inorganic nitrate may attenuate sympathetically oriented pathologies associated with aging.
Importance of Routine Antihuman/Leukocyte Antibody Monitoring
Wong, Ka Lam , Taner, Timuçin , Kushwaha, Sudhir S. , Edwards, Brooks S., Gandhi, Manish J. , Kremers, Walter K. , Daly, Richard C. , Pereira, Naveen L. , Wong, Ka L, Smith, Byron H. , Kremers, Walter K

Mayo Clinic

Circulation | October 2, 2017 | Volume: 136 | Issue: 14 | Pages: 1350-1352

10.1161/circulationaha.117.029964 | PMID 28972064 Get It

Butyrylcholinesterase gene transfer in obese mice prevents postdieting body weight rebound by suppressing ghrelin signaling
Chen, Vicky Ping , Gao, Yang , Geng, Liyi, Brimijoin, Stephen

Mayo Clinic

Proceedings of the National Academy of Sciences | October 2, 2017 | Volume: 114 | Issue: 41 | Pages: 10960-10965

10.1073/pnas.1706517114 | PMID 28973869 Get It

Significance Obesity is a major public health problem affecting physical and emotional well-being. Although lifestyle-based programs can help with weight loss, avoiding weight regain is nearly impossible because of persistent hormonal adaptations. Here, in mouse models, we explored a more effective strategy using viral gene transfer of butyrylcholinesterase (BChE) to control the appetite-mediating hormone acyl-ghrelin. We found that a single injection of BChE vector led to a lifetime high enzyme expression and lower circulating acyl-ghrelin. This same treatment suppressed postdieting hyperphagia, corrected metabolic lesions, and lowered weight regain. This outcome confirms the impact of the BChE-ghrelin axis on body weight and indicates that BChE gene transfer could be a successful strategy for long-term control of obesity and the “metabolic syndrome.”
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Campone, Mario , Sohn, Joohyuk , Paluch–Shimon, Shani , Huober, Jens , Park, In Hae , Trédan, Olivier , Chen, Shin‐Cheh , Manso, Luís , Freedman, Orit, Jaliffe, Georgina Garnica, Forrester, Tammy , Frenzel, Martin, Barriga, Susana , Bourayou, Nawel, Leo, Angelo Di , Toi, Masakazu , Paluch-Shimon, Shani, Freedman, Orit C, Garnica Jaliffe, Georgina, Smith, Ian C., Di Leo, Angelo, Hae Park, In , Di Leo, Angelo , Goetz, Matthew P. , Smith, Ian C., Manso Sanchez, Luis , Sohn, Joohyuk

Mayo Clinic

Journal of Clinical Oncology | October 2, 2017 | Volume: 35 | Issue: 32 | Pages: 3638-3646

10.1200/jco.2017.75.6155 | PMID 28968163 Get It

Purpose Abemaciclib, a cyclin-dependent kinase 4 and 6 inhibitor, demonstrated efficacy as monotherapy and in combination with fulvestrant in women with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer previously treated with endocrine therapy. Methods MONARCH 3 is a double-blind, randomized phase III study of abemaciclib or placebo plus a nonsteroidal aromatase inhibitor in 493 postmenopausal women with HR-positive, HER2-negative advanced breast cancer who had no prior systemic therapy in the advanced setting. Patients received abemaciclib or placebo (150 mg twice daily continuous schedule) plus either 1 mg anastrozole or 2.5 mg letrozole, daily. The primary objective was investigator-assessed progression-free survival. Secondary objectives included response evaluation and safety. A planned interim analysis occurred after 189 events. Results Median progression-free survival was significantly prolonged in the abemaciclib arm (hazard ratio, 0.54; 95% CI, 0.41 to 0.72; P = .000021; median: not reached in the abemaciclib arm, 14.7 months in the placebo arm). In patients with measurable disease, the objective response rate was 59% in the abemaciclib arm and 44% in the placebo arm ( P = .004). In the abemaciclib arm, diarrhea was the most frequent adverse effect (81.3%) but was mainly grade 1 (44.6%). Comparing abemaciclib and placebo, the most frequent grade 3 or 4 adverse events were neutropenia (21.1% v 1.2%), diarrhea (9.5% v 1.2%), and leukopenia (7.6% v 0.6%). Conclusion Abemaciclib plus a nonsteroidal aromatase inhibitor was effective as initial therapy, significantly improving progression-free survival and objective response rate and demonstrating a tolerable safety profile in women with HR-positive, HER2-negative advanced breast cancer.
BubR1 and brain aging
Hussaini, Syed Mohammed Qasim, Jang, Mi‐Hyeon , Hussaini, S. M. Qasim

Mayo Clinic

Aging | October 2, 2017 | Volume: 9 | Issue: 9 | Pages: 1955-1956

10.18632/aging.101300 | PMID 29017149 Get It

Adipose tissue DNA methylome changes in development of new-onset diabetes after kidney transplantation
Baheti, Saurabh , Singh, Prachi , Zhang, Yun , Evans, Jared M., Jensen, Michael D. , Kocher, Jean‐Pierre , Sun, Zhifu , Chakkera, Harini A. , Evans, Jared, Sun, Zhifu , Somers, Virend K. , Singh, Prachi , Chakkera, Harini A

Mayo Clinic

Epigenomics | October 2, 2017 | Volume: 9 | Issue: 11 | Pages: 1423-1435

10.2217/epi-2017-0050 | PMID 28967791 Get It

Lesser Trochanter Osteoplasty for Ischiofemoral Impingement
Goodwin, Jill A., Patel, Karan A. , Hartigan, David E. , Patel, Karan , Chhabra, Anikar

Mayo Clinic

Arthroscopy Techniques | October 2, 2017 | Volume: 6 | Issue: 5 | Pages: No page available

10.1016/j.eats.2017.06.047 | PMID 29399462 Get It

Abstract Ischiofemoral impingement is a newly recognized cause of extra‐articular hip pain, and is caused by contact between the lesser trochanter and ischium. Surgical intervention has been proven successful for patients with persistent pain and disability after failure of nonoperative management. This technique article provides a reliable method for endoscopic lesser trochanter osteoplasty using an anterior approach. Technique Video video See video under supplementary data.
Tracheal decellularization using a combination of chemical, physical and bioreactor methods
Tchoukalova, Yourka D. , Hintze, Justin M. , Hayden, Richard E. , Tchoukalova, Yourka , Hintze, Justin , Lott, David G.

Mayo Clinic

The International Journal of Artificial Organs | October 2, 2017 | Volume: 41 | Issue: 2 | Pages: 100-107

10.5301/ijao.5000648 | PMID 28967085 Get It

Introduction: The purpose of this study was to compare different decellularization protocols with the conventional detergent enzymatic method (DEM) using continuous agitation. Methods: The first experiment compared conventional DEM with sonication and lyophilization+freeze-thaw cycles. A second experiment was carried out to compare time-adjusted DEM (2-hour instead of 4-hour incubations with 4% deoxycholate) to decellularization in a bioreactor. Cellularity was determined by DNA-quantitation, H&E-staining and immunostaining for major histocompatibility complex-1 (MHC-1). Results: Compared to untreated trachea, DNA content significantly decreased after 2 cycles in all groups in the first experiment and dropped below the minimal criteria for efficient decellularization (<50 ng dsDNA/mg dry weight) after 4 cycles. However, nuclei were seen in the cartilage and MCH-1 staining was detected in some submucosal areas, indicating presence of chondrocytes and cellular residues that may render the scaffold immunogenic. In the second experiment DNA content significantly decreased after 1 cycle in both groups; however, even after 4 cycles, DNA content was above the minimal criteria for efficient decellularization. While collagen-levels remained stable, glycosaminoglycans diminished significantly after the initial cycles. Conclusions: Efficient decellularization can be achieved after only 4 cycles of DEM compared to the 17 cycles previously reported. The use of a bioreactor can preserve the integrity of the extracellular matrix.
Communicating Value in Simulation: Cost–Benefit Analysis and Return on Investment
Asche, Carl V. , Kim, Minchul , Brown, Alisha, Golden, Antoinette, Laack, Torrey A. , Rosario, Javier , Strother, Christopher , Totten, Vicken Y. , Okuda, Yasuharu

Mayo Clinic

Academic Emergency Medicine | October 1, 2017 | Volume: 25 | Issue: 2 | Pages: 230-237

10.1111/acem.13327 | PMID 28965366 Get It

AbstractValue‐based health care requires a balancing of medical outcomes with economic value. Administrators need to understand both the clinical and the economic effects of potentially expensive simulation programs to rationalize the costs. Given the often‐disparate priorities of clinical educators relative to health care administrators, justifying the value of simulation requires the use of economic analyses few physicians have been trained to conduct. Clinical educators need to be able to present thorough economic analyses demonstrating returns on investment and cost‐effectiveness to effectively communicate with administrators.At the 2017 Academic Emergency Medicine Consensus Conference “Catalyzing System Change through Health Care Simulation: Systems, Competency, and Outcomes,” our breakout session critically evaluated the cost‐benefit and return on investment of simulation. In this paper we provide an overview of some of the economic tools that a clinician may use to present the value of simulation training to financial officers and other administrators in the economic terms they understand. We also define three themes as a call to action for research related to cost–benefit analysis in simulation as well as four specific research questions that will help guide educators and hospital leadership to make decisions on the value of simulation for their system or program.
Antiepileptic drug‐related neuropsychiatric adverse events in brain tumor‐related epilepsy: levetiracetam front and center
Feyissa, Anteneh M. , Feyissa, A M

Mayo Clinic

European Journal of Neurology | September 30, 2017 | Volume: 24 | Issue: 12 | Pages: 1435-1436

10.1111/ene.13399 | PMID 28963765 Get It

Click here to view the accompanying paper in this volume.